Axsome Therapeutics, Inc. (0HKF.L)
USD 94.11
(0.14%)
USD 94.11
(0.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -224.99 Million USD | -3.0% |
| 2022 | -174.23 Million USD | -37.07% |
| 2021 | -123.55 Million USD | -25.86% |
| 2020 | -99.06 Million USD | -47.66% |
| 2019 | -67.2 Million USD | -105.66% |
| 2018 | -32.58 Million USD | -21.04% |
| 2017 | -27.76 Million USD | 0.41% |
| 2016 | -27.52 Million USD | -291.29% |
| 2015 | -9.19 Million USD | -152.31% |
| 2014 | -2.74 Million USD | -49.06% |
| 2013 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -66.85 Million USD | 32.21% |
| 2024 Q2 | -74.03 Million USD | -19.26% |
| 2023 Q2 | -57.41 Million USD | -1056.63% |
| 2023 Q4 | -117.71 Million USD | -89.49% |
| 2023 Q3 | -62.12 Million USD | -8.19% |
| 2023 Q1 | -4.96 Million USD | 90.76% |
| 2023 FY | - USD | -3.0% |
| 2022 Q4 | -53.69 Million USD | -32.62% |
| 2022 Q2 | -38.76 Million USD | -2.08% |
| 2022 Q1 | -37.97 Million USD | -16.47% |
| 2022 FY | - USD | -37.07% |
| 2022 Q3 | -40.49 Million USD | -4.44% |
| 2021 Q3 | -33.1 Million USD | -8.3% |
| 2021 Q4 | -32.6 Million USD | 1.51% |
| 2021 Q1 | -27.57 Million USD | 0.43% |
| 2021 Q2 | -30.57 Million USD | -10.87% |
| 2021 FY | - USD | -25.86% |
| 2020 FY | - USD | -47.66% |
| 2020 Q3 | -21.12 Million USD | -18.87% |
| 2020 Q2 | -17.77 Million USD | 45.3% |
| 2020 Q1 | -32.49 Million USD | -33.01% |
| 2020 Q4 | -27.69 Million USD | -31.07% |
| 2019 Q1 | -10.41 Million USD | -10.16% |
| 2019 Q4 | -24.42 Million USD | -29.95% |
| 2019 Q3 | -18.79 Million USD | -39.78% |
| 2019 FY | - USD | -105.66% |
| 2019 Q2 | -13.44 Million USD | -29.19% |
| 2018 FY | - USD | -21.04% |
| 2018 Q4 | -9.45 Million USD | -17.94% |
| 2018 Q3 | -8.01 Million USD | -0.29% |
| 2018 Q2 | -7.98 Million USD | -11.72% |
| 2018 Q1 | -7.15 Million USD | -10.97% |
| 2017 FY | - USD | 0.41% |
| 2017 Q1 | -7.66 Million USD | -7.14% |
| 2017 Q3 | -6.07 Million USD | 9.8% |
| 2017 Q2 | -6.74 Million USD | 12.03% |
| 2017 Q4 | -6.44 Million USD | -6.0% |
| 2016 FY | - USD | -291.29% |
| 2016 Q4 | -7.15 Million USD | 0.71% |
| 2016 Q3 | -7.2 Million USD | -5.54% |
| 2016 Q2 | -6.82 Million USD | -16.04% |
| 2016 Q1 | -5.88 Million USD | -92.15% |
| 2015 FY | - USD | -152.31% |
| 2015 Q4 | -3.06 Million USD | -1325.07% |
| 2015 Q3 | 249.82 Thousand USD | 111.1% |
| 2015 Q2 | -2.25 Million USD | -16.43% |
| 2015 Q1 | -1.93 Million USD | 6.77% |
| 2014 FY | - USD | -49.06% |
| 2014 Q1 | -1.2 Million USD | 0.0% |
| 2014 Q4 | -2.07 Million USD | -22.19% |
| 2014 Q3 | -1.69 Million USD | -40.49% |
| 2014 Q2 | -1.2 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -37.932% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2427.654% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 328.971% |
| Perrigo Company plc | 646.2 Million USD | 134.818% |
| Illumina, Inc. | -608 Million USD | 62.995% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 102.083% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 49.892% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 98.005% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 106.91% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -116.771% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 104.834% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -503.468% |
| Waters Corporation | 1.02 Billion USD | 122.009% |
| Biogen Inc. | 2.37 Billion USD | 109.465% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -157.347% |
| Evolus, Inc. | -41.81 Million USD | -438.127% |
| Adicet Bio, Inc. | -136.53 Million USD | -64.786% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -91.238% |
| bluebird bio, Inc. | -167.16 Million USD | -34.595% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -49.886% |
| FibroGen, Inc. | -261.4 Million USD | 13.93% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 113.416% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -406.318% |
| Homology Medicines, Inc. | -47.75 Million USD | -371.126% |
| Geron Corporation | -174.78 Million USD | -28.727% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 1.372% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -144.346% |
| Myriad Genetics, Inc. | -67.8 Million USD | -231.845% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -123.146% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 55.563% |
| Zoetis Inc. | 3.68 Billion USD | 106.106% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -344.892% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 119.328% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 172.511% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 104.886% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -523.555% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 2.182% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 15.416% |
| Verastem, Inc. | -83.16 Million USD | -170.532% |
| Nektar Therapeutics | -243.1 Million USD | 7.452% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -155.715% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 48.772% |
| OPKO Health, Inc. | -65.51 Million USD | -243.414% |
| Exelixis, Inc. | 196.6 Million USD | 214.44% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 154.071% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 307.702% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -303.528% |
| uniQure N.V. | -253.1 Million USD | 11.106% |
| Imunon, Inc. | -20.78 Million USD | -982.61% |
| Blueprint Medicines Corporation | -474.61 Million USD | 52.595% |
| Insmed Incorporated | -654.73 Million USD | 65.637% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 149.783% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 34.873% |
| TG Therapeutics, Inc. | 26.1 Million USD | 962.034% |
| Incyte Corporation | 919.42 Million USD | 124.471% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 55.474% |